Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIPPLE-1: IBE-814 Intravitreal Implant for DMO and RVO
NCT04576689Phase 2Completed
- Sponsor
- Ripple Therapeutics
- Start
- Oct 2020
- Primary completion
- Apr 2023
- Modality
- Implantable Devices, Implantable Hydrogels, Prodrugs/Conditional Activator Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial of IBE-814 IVT in diabetic macular edema (DME) and retinal vein occlusion (RVO) (2 arms), sponsored by Ripple Therapeutics. Primary endpoints: Best Corrected Visual Acuity at 6 months, Central Subfield Thickness at 6 months and 1 more. Started Oct 2020; status: completed.
02
Drugs
IBE-814 IVT
03
Conditions
diabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT04576689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576689.